EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers

Yueh-Hsiang Yu iD, Wei-Ting Tian iD, Cédric Grauffel iD, Wei-Chen Lin iD, Ming-Yu Hsieh, Pei-Wen Wu iD, Hui-Ju Lee iD, Chi-Jiun Peng iD, Pei-Hsuan Lin, Hsing-Mao Chu iD, Carmay Lim iD, Tse Wen Chang iD

Advanced Science · 2024-05 · 11 (20)

DOI: 10.1002/advs.202307852 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 13.03.2024. Verfasst von Yueh-Hsiang Yu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Immunwork, Inc., Academia Rd., Sec. 1, Nangang, Taipei, 115, Taiwan. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunoconjugates, Lenalidomide, Antibodies, Monoclonal. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Immunwork, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

First‐line treatment of multiple myeloma, a prevalent blood cancer lacking a cure, using anti‐CD38 daratumumab antibody and lenalidomide is often inadequate due to relapse and severe side effects. To enhance drug safety and efficacy, an antibody‐drug conjugate, TE‐1146, comprising six lenalidomide drug molecules site‐specifically conjugated to a reconfigured daratumumab to deliver cytotoxic lenalidomide to tumor cells is developed. TE‐1146 is prepared using the HighDAR platform, which employs i) a maleimide‐containing “multi‐arm linker” to conjugate multiple drug molecules creating a drug bundle, and ii) a designed peptide with a Zn 2+ ‐binding cysteine at the C‐termini of a reconfigured daratumumab for site‐specific drug bundle conjugation. It is shown that TE‐1146 remains intact and effectively enters CD38‐expressing tumor cells, releasing lenalidomide, leading to enhanced cell‐killing effects compared to lenalidomide/daratumumab alone or their combination. This reveals the remarkable potency of lenalidomide once internalized by myeloma cells. TE‐1146 precisely delivers lenalidomide to target CD38‐overexpressing tumor cells. In contrast, lenalidomide without daratumumab cannot easily enter cells, whereas daratumumab without lenalidomide relies on Fc‐dependent effector functions to kill tumor cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaImmunoconjugatesLenalidomideAntibodies, MonoclonalHumansCell Line, TumorAntineoplastic AgentsMiceAnimalsDisease Models, Animal

Stichwörter der Autor:innen

Zn2+‐binding motifanti‐CD38lenalidomidescFvsite‐specific conjugation

Substanzen

ImmunoconjugatesLenalidomidedaratumumabAntibodies, MonoclonalAntineoplastic Agents

Autor:innen und Institutionen

  • Immunwork, Inc., Academia Rd., Sec. 1, Nangang, Taipei, 115, Taiwan.
  • Institute of Biomedical Sciences, Academia Sinica, Academia Rd., Taipei, 115, Taiwan.

ORCID-Profile: Yueh-Hsiang Yu, Wei-Ting Tian, Cédric Grauffel, Wei-Chen Lin, Pei-Wen Wu, Hui-Ju Lee, Chi-Jiun Peng, Hsing-Mao Chu, Carmay Lim, Tse Wen Chang

Förderung

  • Immunwork, Inc.

Zitieren

APA

Yu, Y. H., Tian, W. T., Grauffel, C., Lin, W. C., Hsieh, M. Y., Wu, P. W., Lee, H. J., Peng, C. J., Lin, P. H., Chu, H. M., Lim, C., & Chang, T. W. (2024). An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers. Advanced Science, 11(20). https://doi.org/10.1002/advs.202307852

Vancouver

Yu YH, Tian WT, Grauffel C, Lin WC, Hsieh MY, Wu PW, et al. An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers. Advanced Science. 2024;11(20). doi:10.1002/advs.202307852

BibTeX
@article{Yu2024,
  author = {Yu, Yueh-Hsiang and Tian, Wei-Ting and Grauffel, Cédric and Lin, Wei-Chen and Hsieh, Ming-Yu and Wu, Pei-Wen and Lee, Hui-Ju and Peng, Chi-Jiun and Lin, Pei-Hsuan and Chu, Hsing-Mao and Lim, Carmay and Chang, Tse Wen},
  title = {An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {20},
  doi = {10.1002/advs.202307852}
}
Kostenlos starten →